Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: The role of treatment order
Edith A. Perez
Hematology / Oncology / Cancer Center / Breast Clinic
Research output
:
Contribution to journal
›
Article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: The role of treatment order'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
human ERBB2 protein
100%
Hormones
57%
Breast Neoplasms
52%
palbociclib
20%
Cyclin-Dependent Kinase 6
19%
Cyclin-Dependent Kinase 4
17%
Therapeutics
13%
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
13%
Alpelisib
11%
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
11%
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
11%
ribociclib
11%
NVP-BKM120
10%
entinostat
10%
Survival Rate
9%
exemestane
9%
Letrozole
8%
Fulvestrant
8%
Estrogen Receptor Modulators
8%
Everolimus
7%
Oncologists
6%
Phosphatidylinositol 3-Kinases
6%
Estrogen Receptors
5%
Neoplasm Metastasis
3%
Mutation
3%
Genes
2%